Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 304-312

  Zhao, Libo ^a   Wang, Xiaomin ^a   Chang, Qing ^a   Xu, Junying ^a   Huang, Ying ^a   Guo, Qiuyun ^a   Zhang, Shaohui ^a   Wang, Wenquan ^a   Chen, Xiujuan ^a   Wang, Jialing ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

(Mouse); Bleomycin; Macrophage; Neferine; Pulmonary fibrosis

Indexed keywords

BISBENZYLISOQUINOLINE ALKALOID; BLEOMYCIN; CYTOKINE; ENDOTHELIN 1; HYDROXYPROLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MALONALDEHYDE; MYELOPEROXIDASE; NEFERINE; PIRFENIDONE; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MACROPHAGE; MOUSE; NELUMBO; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RADIOIMMUNOASSAY; SHAM PROCEDURE; STRUCTURE ANALYSIS;

ANIMALS; BENZYLISOQUINOLINES; BLEOMYCIN; CELL LINE; CELL PROLIFERATION; CYTOKINES; ENDOTHELIN-1; GENE EXPRESSION REGULATION; HYDROXYPROLINE; INFLAMMATION; INTERLEUKIN-6; MICE; NF-KAPPA B; OXIDATIVE STRESS; PULMONARY FIBROSIS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 73449146238     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.11.007     Document Type: Article

References (61)

1. Antoniu S.A. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Investig. Drugs 15 (2006) 823-828
2. Ashcroft T., Simpson J.M., and Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41 (1988) 467-470
3. Ask K., Martin G.E., Kolb M., and Gauldie J. Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. Proc. Am. Thorac. Soc. 3 (2006) 389-393
4. Bois R.M.d. Blocking endothelin: breaking new ground. Eur. Respir. Rev. 16 (2007) 24-29
5. Bolt M.W., Racz W.J., Brien J.F., and Massey T.E. Effects of vitamin E on cytotoxicity of amiodarone and N-desethylamiodarone in isolated hamster lung cells. Toxicology 166 (2001) 109-118
6. Boyaci H., Maral H., Turan G., Basyigit I., Dillioglugil M.O., Yildiz F., Tugay M., Pala A., and Ercin C. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol. Cell. Biochem. 281 (2006) 129-137
7. Caiying H., and Qiutang Z. Neferine on lipids accumulation in VSMC and proliferation of VSMCs induced by oxLDL. Natl. Med. J. China 30 (2006) 401-403
8. Card J.W., Racz W.J., Brien J.F., Margolin S.B., and Massey T.E. Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. Toxicol. Sci. 75 (2003) 169-180
9. Card J.W., Racz W.J., Brien J.F., and Massey T.E. Attenuation of amiodarone-induced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction. J. Pharmacol. Exp. Ther. 304 (2003) 277-283
10. Carter J.M., and Driscoll K.E. The role of inflammation, oxidative stress, and proliferation in silica-induced lung disease: a species comparison. J. Environ. Pathol. Toxicol. Oncol. 20 Suppl 1 (2001) 33-43
11. Chaudhary N.I., Schnapp A., and Park J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 173 (2006) 769-776
12. Cuzzocrea S., Genovese T., Failla M., Vecchio G., Fruciano M., Mazzon E., Di Paola R., Muia C., La Rosa C., Crimi N., Rizzarelli E., and Vancheri C. Protective effect of orally administered carnosine on bleomycin-induced lung injury. Am. J. Physiol., Lung Cell. Mol. Physiol. 292 (2007) L1095-1104
13. Daba M.H., El-Tahir K.E., Al-Arifi M.N., and Gubara O.A. Drug-induced pulmonary fibrosis. Saudi Med. J. 25 (2004) 700-706
14. Daniels C.E., and Ryu J.H. Treatment of idiopathic pulmonary fibrosis. Semin. Respir. Crit. Care Med. 27 (2006) 668-676
15. Douglas W.W., Ryu J.H., and Schroeder D.R. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 161 (2000) 1172-1178
16. Dury S. Treatment of idiopathic pulmonary fibrosis. Rev. Mal. Respir. 23 (2006) 5S87-85S91
17. Fubini B., and Hubbard A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic. Biol. Med. 34 (2003) 1507-1516
18. Giri S.N. The combined treatment with taurine and niacin blocks the bleomycin-induced activation of nuclear factor-kappaB and lung fibrosis. Adv. Exp. Med. Biol. 526 (2003) 381-394
19. Gunella G., Bardelli C., Amoruso A., Viano I., Balbo P., and Brunelleschi S. Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway. Br. J. Pharmacol. 148 (2006) 478-489
20. GuoZhibin L., and CaoHongyu X. Antiarrhythmic efficacy of neferine assessed by programmed electrical stimulation in a canine model of electropharmacology. J. Chin. Pharm. Sci. 11 (2002) 35-42
21. Hartl D., Starosta V., Maier K., Beck-Speier I., Rebhan C., Becker B.F., Latzin P., Fischer R., Ratjen F., Huber R.M., Rietschel E., Krauss-Etschmann S., and Griese M. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic. Biol. Med. 39 (2005) 463-472
22. Hoshino T., Nakamura H., Okamoto M., Kato S., Araya S., Nomiyama K., Oizumi K., Young H.A., Aizawa H., and Yodoi J. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am. J. Respir. Crit. Care Med. 168 (2003) 1075-1083
23. Hsu Y.C., Chiu Y.T., Lee C.Y., Wu C.F., and Huang Y.T. Anti-fibrotic effects of tetrandrine on bile-duct ligated rats. Can. J. Physiol. Pharmacol. 84 (2006) 967-976
24. Huang Y., Bai Y., Zhao L., Hu T., Hu B., Wang J., and Xiang J. Pharmacokinetics and metabolism of neferine in rats after a single oral administration. Biopharm. Drug Dispos. 28 (2007) 361-372
25. Inayama M., Nishioka Y., Azuma M., Muto S., Aono Y., Makino H., Tani K., Uehara H., Izumi K., Itai A., and Sone S. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 173 (2006) 1016-1022
26. Iyer S.N., Hyde D.M., and Giri S.N. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 24 (2000) 477-491
27. JF W.J. The determination of hydroxyline in tissue and protein samples containing small proportions of this amino acid. Arch. Biochem. Biophys. 93 (1961) 440-444
28. Kakugawa T., Mukae H., Hayashi T., Ishii H., Abe K., Fujii T., Oku H., Miyazaki M., Kadota J., and Kohno S. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur. Respir. J. 24 (2004) 57-65
29. Kinnula V.L., Fattman C.L., Tan R.J., and Oury T.D. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am. J. Respir. Crit. Care Med. 172 (2005) 417-422
30. Krishna G., Liu K., Shigemitsu H., Gao M., Raffin T.A., and Rosen G.D. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am. J. Pathol. 158 (2001) 997-1004
31. 2+ in guinea pig atria. Yao Xue Xue Bao 23 (1988) 241-245
32. Li W., Antholine W.E., and Petering D.H. Kinetics of reaction of DNA-bound Fe(III)bleomycin with ascorbate: interplay of specific and non-specific binding. J. Inorg. Biochem. 90 (2002) 8-17
33. Lizhong L., and Guohui L. Influence of neferine on proliferation of hypertrophic scar fibroblasts in vitro. Chin. Tradit. Herb. Drugs 33 (2002) 1018-1020
34. Lizhong L., Guohui L., Jianhua F., Wei L., Wenfang L., and Honghua Y. Influences of neferine on synthesis of collagen and acidic mucopolysaccharide in hypertrophic scars in nude mice. Acta Acad. Med. Jiangxi 43 (2003) 19-22
35. Mastruzzo C., Crimi N., and Vancheri C. Role of oxidative stress in pulmonary fibrosis. Monaldi Arch. Chest Dis. 57 (2002) 173-176
36. Mata M., Ruiz A., Cerda M., Martinez-Losa M., Cortijo J., Santangelo F., Serrano-Mollar A., Llombart-Bosch A., and Morcillo E.J. Oral N-acetylcysteine reduces bleomycin-induced lung damage and mucin Muc5ac expression in rats. Eur. Respir. J. 22 (2003) 900-905
37. Mizuguchi S., Takemura S., Minamiyama Y., Kodai S., Tsukioka T., Inoue K., Okada S., and Suehiro S. S-allyl cysteine attenuated CCl4-induced oxidative stress and pulmonary fibrosis in rats. Biofactors 26 (2006) 81-92
38. Morelli S., and Ferri C. Circulating endothelin-1 levels in systemic sclerosis subsets-a marker of fibrosis or vascular dysfunction?. J. Rheumatol. 23 (1996) 789-791
39. Ogawa K., Chen F., Kuang C., and Chen Y. Suppression of matrix metalloproteinase-9 transcription by transforming growth factor-beta is mediated by a nuclear factor-kappaB site. Biochem. J. 381 (2004) 413-422
40. Ota K. Diagnosis and treatment of idiopathic pulmonary fibrosis. Nippon Naika Gakkai Zasshi 96 (2007) 557-561
41. Qian J.Q. Cardiovascular pharmacological effects of bisbenzylisoquinoline alkaloid derivatives. Acta Pharmacol. Sin. 23 (2002) 1086-1092
42. Raghu G. Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur. Respir. J. 28 (2006) 463-465
43. Reid D.W., Misso N., Aggarwal S., Thompson P.J., and Walters E.H. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis. Respirology 12 (2007) 63-69
44. Ren Y.X., Zhou R., Tang W., Wang W.H., Li Y.C., Yang Y.F., and Zuo J.P. (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice. Acta Pharmacol. Sin. 28 (2007) 518-525
45. Saadane A., Masters S., DiDonato J., Li J., and Berger M. Parthenolide inhibits IkappaB kinase, NF-kappaB activation, and inflammatory response in cystic fibrosis cells and mice. Am. J. Respir. Cell Mol. Biol. 36 (2007) 728-736
46. Selman M., Navarro C., and Gaxiola M. Idiopathic pulmonary fibrosis: in search of an effective treatment. Arch. Bronconeumol. 41 (2005) 15-20
47. Shishodia S., Singh T., and Chaturvedi M.M. Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol. 595 (2007) 127-148
48. Sofia M., Mormile M., Faraone S., Alifano M., Carratu P., and Carratu L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis 12 (1995) 118-123
49. Tian X.L., Yao W., Guo Z.J., Gu L., and Zhu Y.J. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin. Med. Sci. J. 21 (2006) 145-151
50. Uguccioni M., Pulsatelli L., Grigolo B., Facchini A., Fasano L., Cinti C., Fabbri M., Gasbarrini G., and Meliconi R. Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. 48 (1995) 330-334
51. Usuki K.F.Y. Evolution of three patterns of intra-alveolar fibrosis produced by bleomycin in rats. Pathol. Int. 45 (1995) 552-564
52. Walter N., Collard H.R., and King Jr. T.E. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 3 (2006) 330-338
53. Wang J.Y., Chuang H.N., Chiu J.H., Fu S.L., Tsai T.H., Tsou A.P., Hu C.P., Chi C.W., Yeh S.F., Lui W.Y., Wu C.W., and Chou C.K. Effects of Scutellaria baicalensis Georgi on macrophage-hepatocyte interaction through cytokines related to growth control of murine hepatocytes. Exp. Biol. Med. (Maywood) 231 (2006) 444-455
54. Wei Z., Jie Z., Juan C., Rong C., and Youmei F. Effect of neferine on RAW264.7 foam cell formation. J. Med. Mol. Biol. 2 (2005) 170-174
55. Xiao J.H., Zhang J.H., Chen H.L., Feng X.L., and Wang J.L. Inhibitory effects of isoliensinine on bleomycin-induced pulmonary fibrosis in mice. Planta Med. 71 (2005) 225-230
56. Sun Y., and Oberley L.W. Redox regulation of transcriptional activators. Free Radic. Biol. Med. 21 (1996) 335-348
57. Yara S., Kawakami K., Kudeken N., Tohyama M., Teruya K., Chinen T., Awaya A., and Saito A. FTS reduces bleomycin-induced cytokine and chemokine production and inhibits pulmonary fibrosis in mice. Clin. Exp. Immunol. 124 (2001) 77-85
58. Yildirim Z., Kotuk M., Iraz M., Kuku I., Ulu R., Armutcu F., and Ozen S. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine. Pulm. Pharmacol. Ther. 18 (2005) 367-373
59. Yildirim Z., Turkoz Y., Kotuk M., Armutcu F., Gurel A., Iraz M., Ozen S., Aydogdu I., and Akyol O. Effects of aminoguanidine and antioxidant erdosteine on bleomycin-induced lung fibrosis in rats. Nitric Oxide 11 (2004) 156-165
60. Yu J., and Hu W.S. Effects of neferine on platelet aggregation in rabbits. Yao Xue Xue Bao 32 (1997) 1-4
61. Zhang X.Y., Zhou Y., Liu W.Q., Zhao L., and Li S.Q. Effects of antisense oligonucleotide to nuclear factor-kappaB on the development of bleomycin-induced pulmonary fibrosis and IL-4 expression therein: experiment with mice. Zhonghua Yixue Zazhi 87 (2007) 195-199